# Chemomab Therapeutics Ltd.: overview CMMB · Nasdaq · CIK 1534248 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cmmb.md) · [Financials](/companies/cmmb/financials.md) · [Filings](/companies/cmmb/filings.md) · [Insiders](/companies/cmmb/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q2 FY2021 (2021-06-30) | Q3 FY2021 (2021-09-30) | Q4 FY2021 (2021-12-31) | Q1 FY2022 (2022-03-31) | Q2 FY2022 (2022-06-30) | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.01](/filings/0001178913-22-003074.md) | [0.01](/filings/0001178913-22-003931.md) | not reported | [0.02](/filings/0001178913-23-001807.md) | [0.03](/filings/0001178913-22-003074.md) | [0.04](/filings/0001178913-22-003931.md) | not reported | [0.04](/filings/0001178913-23-001807.md) | | Free cash flow | $k | [(5,709) d](/filings/0001178913-22-003074.md) | [(2,580) d](/filings/0001178913-22-003931.md) | [(3,028) d](/filings/0001178913-24-001124.md) | [(3,725)](/filings/0001178913-23-001807.md) | [(5,712) d](/filings/0001178913-22-003074.md) | [(5,297) d](/filings/0001178913-22-003931.md) | [(5,704) d](/filings/0001178913-25-001205.md) | [(7,187)](/filings/0001178913-23-001807.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL not reported. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 6-month figure less the 3-month figure; 9-month figure less the 6-month figure; 12-month figure less the 9-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [0.06](/filings/0001178913-24-001124.md) | [0.12](/filings/0001178913-25-001205.md) | [0.10](/filings/0001178913-26-001593.md) | [0.04](/filings/0001178913-26-001593.md) | [0.02](/filings/0001178913-26-001593.md) | | Free cash flow | $m | [(12.6)](/filings/0001178913-24-001124.md) | [(20.4)](/filings/0001178913-25-001205.md) | [(23.6)](/filings/0001178913-26-001593.md) | [(15.4)](/filings/0001178913-26-001593.md) | [(11.1)](/filings/0001178913-26-001593.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cmmb/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $154.4k | 95,311 | | Added +31,129 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $129.6k | 80,000 | | Unchanged | | [KESTRA PRIVATE WEALTH SERVICES, LLC](/funds/1649451.md) | 2026-06-30 | $100.0k | 61,710 | | Unchanged | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $83.9k | 51,793 | | Unchanged | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $49.5k | 30,529 | | Added +12,163 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $25.9k | 15,987 | | Reduced −2,642 | | [Philadelphia Investment Partners, LLC](/funds/2131511.md) | 2026-06-30 | $24.3k | 15,000 | | Added +6,800 | | [Lido Advisors, LLC](/funds/1650150.md) | 2026-06-30 | $23.2k | 14,341 | | New +14,341 | | [BNP PARIBAS FINANCIAL MARKETS](/funds/1166588.md) | 2026-06-30 | $11.0k | 6,805 | | Reduced −1,620 | | [GAMMA Investing LLC](/funds/2010235.md) | 2026-06-30 | $7.7k | 4,740 | | Reduced −2,839 | ## Recent filings [All 360 filings](/companies/cmmb/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-19 | 17:28 ET | [6-K](/filings/0001178913-26-004796.md) | Report of a foreign private issuer, period 2026-10-19 | 0001178913-26-004796 | | 2026-09-30 | 16:05 ET | [6-K](/filings/0001178913-26-004676.md) | Report of a foreign private issuer, period 2026-09-30 | 0001178913-26-004676 | | 2026-09-09 | 16:00 ET | [SCHEDULE 13D/A](/filings/0001104659-26-106301.md) | Ownership report, active investor, amended | 0001104659-26-106301 | | 2026-08-19 | 09:16 ET | [6-K](/filings/0001178913-26-004193.md) | Report of a foreign private issuer, period 2026-06-30 | 0001178913-26-004193 | | 2026-07-16 | 16:05 ET | [SCHEDULE 13D](/filings/0001104659-26-084244.md) | Ownership report, active investor | 0001104659-26-084244 | | 2026-07-08 | 07:34 ET | [6-K](/filings/0001178913-26-003442.md) | Report of a foreign private issuer, period 2026-07-08 | 0001178913-26-003442 | | 2026-06-02 | 16:03 ET | [6-K](/filings/0001178913-26-003058.md) | Report of a foreign private issuer, period 2026-06-02 | 0001178913-26-003058 | | 2026-05-14 | 08:00 ET | [6-K](/filings/0001178913-26-002672.md) | Report of a foreign private issuer, period 2026-05-14 | 0001178913-26-002672 | | 2026-05-06 | 17:03 ET | [6-K](/filings/0001178913-26-002423.md) | Report of a foreign private issuer, period 2026-05-06 | 0001178913-26-002423 | | 2026-04-28 | 16:06 ET | [6-K](/filings/0001178913-26-002274.md) | Report of a foreign private issuer, period 2026-04-28 | 0001178913-26-002274 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001178913-26-001593.md), filed Mar 23, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1534248 - Tickers: CMMB - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: L3 - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 17:20 ET. No prices; not investment advice.